Boc-L-Ala-OH
Based on 1 publication(s) in Google Scholar
Boc-L-Ala-OH (Boc-Ala-OH) is a single N-protected amino acid ligand and a protected L-alanine derivative. Boc-L-Ala-OH promotes Pd (II)-catalyzed enantioselective C-H alkenylation and kinetic resolution. Boc-L-Ala-OH serves as a coupling reagent for the synthesis of liver-targeted glycogen phosphorylase inhibitors and P6A metabolites, and also acts as a negative control in synthesis studies of betulinic acid amino acid esters. Boc-L-Ala-OH is applicable to research on epidermoid squamous cell carcinoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.07%
- No. CAS: 15761-38-3
- Fòrmula: C8H15NO4
- Peso molecular:189.21
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-Y1164
N-tert-Butoxycarbonyl-D-alanine
-
HY-79096
Boc-L-phenylalanine
-
HY-W007618
Boc-Lys-OH
-
HY-W014663
(S)-2-((tert-Butoxycarbonyl)amino)-3-hydroxypropanoic acid
-
HY-W009502
(tert-Butoxycarbonyl)-L-methionine
-
![(2S)-4-(Benzyloxy)-2-[(tert-butoxycarbonyl)amino]-4-oxobutanoic acid](https://file.medchemexpress.com/product_pic/hy-z0615.gif)
HY-Z0615
(2S)-4-(Benzyloxy)-2-[(tert-butoxycarbonyl)amino]-4-oxobutanoic acid
-
HY-W002294
(tert-Butoxycarbonyl)-D-serine
-
HY-W002300
Boc-L-Valine
-
HY-Y0978
Boc-Glycine
-
HY-W013292
(S)-2-((tert-Butoxycarbonyl)amino)-3-(4-hydroxyphenyl)propanoic acid
-
HY-Z0438
Boc-L-Ile-OH
-
HY-41257
Boc-L-Tyrosine methyl ester
Publications Citing Use of MedChemExpress (MCE) Boc-L-Ala-OH
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | GI50 |
>100 nM
Compound: 16
|
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by 365 nm light irradiation for 5 mins and measured 72 hrs post compound treatment by CellTit
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by 365 nm light irradiation for 5 mins and measured 72 hrs post compound treatment by CellTit
|
[PMID: 36924668] |
| A-375 | GI50 |
>100 μM
Compound: 16
|
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay
|
[PMID: 36924668] |
| HEK-293T | GI50 |
>100 μM
Compound: 16
|
Cytotoxicity against HEK293T cells assessed as cell growth inhibition preincubated with compound for 1 hrs followed by 365 nm light irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo luminescent assay
Cytotoxicity against HEK293T cells assessed as cell growth inhibition preincubated with compound for 1 hrs followed by 365 nm light irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo luminescent assay
|
[PMID: 36924668] |
Boc-L-Ala-OH (0.20-0.80 mmol; 0 °C) is used to synthesize two protected peptide intermediates, Boc-Ala-Arg (NO2)-Pro-OBzl and Boc-Ala-Arg (NO2)-Pro-Ala-OBzl, via solution-phase stepwise coupling and deprotection reactions, with yields of 87% and 80%, respectively[4].
Boc-L-Ala-OH (0.20 mmol; RT; 24 h) can be incorporated into Boc-Ala-Arg (NO2)-Pro-OBzl and Boc-Ala-Arg (NO2)-Pro-Ala-OBzl, and after deprotection, H-Ala-Arg-Pro-OH and H-Ala-Arg-Pro-Ala-OH are obtained with yields of 86% and 85%, respectively[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 15761-38-3
-
Appearance Solid
-
Peso molecular 189.21
-
Fòrmula C8H15NO4
-
Color White to off-white
-
Synonyms
Boc-Ala-OH
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Chembiochem
Design, Synthesis and Catalytic Activity of Protein Containing Thiotyrosine as an Active Site Residue. [Abstract]2024 Sep 2;25(17):e202400148. PMID: 38629812
Solvente y solubilidad
DMSO : 100 mg/mL (528.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[2]. Drąg-Zalesińska M, et al. The new esters derivatives of betulin and betulinic acid in epidermoid squamous carcinoma treatment - In vitro studies. Biomed Pharmacother. 2015;72:91-97. [Content Brief]
[3]. Zhang L, et al. Novel Liver-targeted conjugates of Glycogen Phosphorylase Inhibitor PSN-357 for the Treatment of Diabetes: Design, Synthesis, Pharmacokinetic and Pharmacological Evaluations. Sci Rep. 2017;7:42251. Published 2017 Feb 22. [Content Brief]
[4]. Zhao M, et al. Identification, synthesis and bioassay for the metabolites of P6A. Bioorg Med Chem. 2003;11(23):4913-4920. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.2851 mL | 26.4257 mL | 52.8513 mL | 132.1283 mL |
| 5 mM | 1.0570 mL | 5.2851 mL | 10.5703 mL | 26.4257 mL | |
| 10 mM | 0.5285 mL | 2.6426 mL | 5.2851 mL | 13.2128 mL | |
| 15 mM | 0.3523 mL | 1.7617 mL | 3.5234 mL | 8.8086 mL | |
| 20 mM | 0.2643 mL | 1.3213 mL | 2.6426 mL | 6.6064 mL | |
| 25 mM | 0.2114 mL | 1.0570 mL | 2.1141 mL | 5.2851 mL | |
| 30 mM | 0.1762 mL | 0.8809 mL | 1.7617 mL | 4.4043 mL | |
| 40 mM | 0.1321 mL | 0.6606 mL | 1.3213 mL | 3.3032 mL | |
| 50 mM | 0.1057 mL | 0.5285 mL | 1.0570 mL | 2.6426 mL | |
| 60 mM | 0.0881 mL | 0.4404 mL | 0.8809 mL | 2.2021 mL | |
| 80 mM | 0.0661 mL | 0.3303 mL | 0.6606 mL | 1.6516 mL | |
| 100 mM | 0.0529 mL | 0.2643 mL | 0.5285 mL | 1.3213 mL |
Boc-L-Ala-OH Related Classifications
HY-41121 Related Classifications
Powered by Bioz
- Boc-L-Ala-OH
- 15761-38-3
- Boc-Ala-OH
- Amino Acid Derivatives
- protected L-alanine derivative
- racemic pivaloyl-protected 3-chloromandelic acid
- mono-N-protected amino acid ligand
- epidermoid squamous carcinoma
- betulin amino acid esters
- P6A metabolites
- protected peptide intermediates
- Pd(II)-catalyzed enantioselective C-H olefination/kinetic resolution
- peptide synthesis
- liver-targeted glycogen phosphorylase inhibitor conjugates
- Inhibitor
- inhibitor
- inhibit